Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that production of a proprietary GABA drug has started. Concurrently, the Scientific and Medical Advisory Board is expanded with two leading experts in rheumatoid arthritis and type 2 diabetes, Professor Daniel Furst, University of California, Los Angeles (UCLA) and Associate Professor Michael Alvarsson, Clinic Director at the Karolinska University Hospital.Diamyd Medical has as previously reported broadened its operations to include type 2 diabetes and rheumatoid arthritis with its own GABA drug. Development of a GABA-